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Abstract 
SS18–SSX (formerly called SYT–SSX) fusion gene has been established clinically as a molecular diagnostic test for 
synovial sarcoma, but the prognostic value of the fusion gene variant for survival is controversial. The objective of this 
systematic review is to provide an up-to-date and unprecedented summary of the prognostic impact of SS18–SSX 
fusion type in synovial sarcoma. Studies evaluating SS18–SSX fusion type as a prognostic marker in synovial sarcoma 
were systematically searched for in MEDLINE, EMBASE, and Web of Science. Comparative analysis of the pooled hazard 
ratios (HR) between fusion types was carried out, in order to assess the likelihood of overall survival (OS), disease-
specific survival (DSS), progression-free survival (PFS), and metastasis-free survival (MFS). A total of 10 studies compris-
ing 902 patients with synovial sarcoma were considered for the meta-analysis. The pooled HR for eight eligible studies 
evaluating for OS or DSS was 1.28 (95% confidence interval: 0.81–2.00), suggesting no significant difference between 
SS18–SSX1 and SS18–SSX2 (P = 0.29). For seven studies which evaluated for PFS or MFS, the presence of SS18–SSX1 
may indicate a lower survival probability than that of SS18–SSX2, although the effect did not reach a level of statisti-
cal significance (P = 0.09). There was no significant difference in OS or DSS between SS18–SSX1 and SS18–SSX2, but 
there were indications of SS18–SSX1 being an unfavorable prognostic factor of PFS or MFS. Further studies including 
cohorts with a longer follow-up period are needed.
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Background
Synovial sarcoma, accounting for 7–10% of all soft tis-
sue sarcoma, most commonly occurs in the extremities 
of young adults. Recent therapeutic progress in surgery, 
chemotherapy, and radiotherapy has improved the prog-
nosis of survival, with a 5-year overall survival rate of 
50–80%, and several prognostic factors being reported 
such as patient’s age, tumor size, and histological grade 
(Lewis et  al. 2000; Spillane et  al. 2000; Bergh et  al. 
1999). A recurrent chromosomal translocation, t(X;18)
(p11.2;q11.2), fuses the SS18 (formerly called SYT) gene 
on chromosome 18 to SSX1, SSX2, or, rarely, SSX4 on 
the X chromosome (Clark et  al. 1994). Since SS18–SSX 
(formerly called SYT–SSX) fusion gene can be found in 
more than 95% of synovial sarcoma by reverse transcrip-
tion-polymerase chain reaction or fluorescent in  situ 
hybridization, it is considered to be an established clini-
cally diagnostic marker for this type of tumor. Moreover, 
this translocation is regarded as a chimeric fusion onco-
gene in the development of synovial sarcoma.
The extent of the prognostic significance of SS18T–SSX 
fusion gene variant remains unclear. The first small report 
by Kawai et  al. (1998) statistically showed that patients 
with tumors bearing SS18–SSX2 had a better metastasis-
free survival (MFS) rate than those with SS18–SSX1. A 
large study reported by the same institute did not proved 
a significant difference in overall survival (OS) for all 
patients, but showed that only for those without metas-
tasis at diagnosis, suggesting that once a tumor metas-
tasizes, this event outweighs any prognostic influence of 
the fusion gene (Ladanyi et al. 2002). A multi-institutional 
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study of 141 patients in Europe did not show any corre-
lation between the fusion gene and the likelihood of any 
survival (Guillou et  al. 2004). If the SS18–SSX fusion 
type is associated with survival outcomes, it should play 
an important role in tumor cell behavior, affecting its ini-
tiation, progression, and metastatic activity. However, 
the results of studies looking for a relationship between 
the fusion type and tumor cell proliferation are also con-
troversial. Two studies have demonstrated a higher cell 
proliferation in SS18–SSX1 tumors (Skytting 2000; Ina-
gaki et  al. 2000). Conversely, Guillou et al.’s (2004) study 
showed that SS18–SSX1 tumors tended to be less necrotic 
than SS18–SSX2, but there was no difference in the 
degree of differentiation or mitotic activity between them.
The purpose of this systematic review is to provide an 
up-to-date and unprecedented summary of the prognos-
tic value of SS18–SSX fusion type in synovial sarcoma. 
We used a systematic literature search and meta-anal-
ysis to compare the difference in survival rates of syno-




A systematic search was performed according to the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement (Liberati et al. 2009). The 
main research question was defined using the Target 
Population, Index Test, Comparator Test, Outcome, and 
Study design (PICOS) strategy, which was formulated 
into a search query. A search based on a combination of 
the terms ‘‘synovial sarcoma’’, “survival”, and ‘‘SYT–SSX or 
SS18–SSX’’ was performed without a time search limi-
tation, using the following three search engines: MED-
LINE, EMBASE, and Web of Science.
Study selection
Two reviewers (TK and TF) independently assessed poten-
tially relevant articles for eligibility using predetermined 
criteria. The procedure to include or exclude articles was 
hierarchical and initially based on the study title, then on 
the study abstract, and finally on the full study article.
The inclusion criteria were: (1) original English arti-
cles; (2) to evaluate SS18–SSX fusion gene as a prognos-
tic factor in synovial sarcoma; (3) sufficient raw data to 
estimate the log hazard ratio (logHR) and standard error 
(SE) for OS, disease-specific survival (DSS), progression-
free survival (PFS) or MFS of patients with SS18–SSX1 
compared with those with SS18–SSX2; (4) studies with 
a sample size of 30 or more. When subsets of data were 
reported in more than one article, the most recent article 
was chosen.
Data extraction
The two investigators (TK and JF) independently 
reviewed the included articles and extracted the follow-
ing information on time-to-event data: the hazard ratio 
(HR) and 95% confidence interval (95% CI), P values of 
the log-rank test and event numbers, or raw data of all 
patients. Then, the methods provided by Parmar et  al. 
(1998) and Tierney et  al. (2007) were used to convert 
such data into the logHR and SE.
Quality assessment
The quality of study designs was evaluated using the 
Newcastle–Ottawa scale (NOS) for quality assessment 
of cohort studies (Stang 2010). A star system of the NOS 
has been developed for the evaluation, the highest value 
being nine stars.
Meta‑analysis
Meta-analysis was conducted using the generic inverse-
variance method. Heterogeneity of the HR of each study 
was assessed by the inconsistency index I-square (I2) test 
as well as by the χ2 test. An I2  >  50% and/or P  <  0.05 
was considered statistically significant. A random effect 
model (Der Simonian and Laird method) was applied if 
heterogeneity was observed, while a fixed effect model 
was used in the absence of between-study heterogeneity 
(I2 < 50%, P > 0.05). Publication bias was estimated using 
funnel plot asymmetry tests. All meta-analysis was per-
formed using Review Manager software, v. 5 (Cochrane 
Collaboration, Oxford, UK). P < 0.05 was defined as sta-
tistically significant.
Results
Literature search and selection of studies
The main research question according to PICOS was P, 
patients with synovial sarcoma; I, the presence of SS18–
SSX1 fusion gene; C, the presence of SS18–SSX2 fusion 
gene; O, OS, DSS, PFS and/or MFS; S, retrospective 
cohort studies. Using the predefined search strategy, we 
identified 117 potentially eligible articles, of which 52 
were excluded due to duplication and 50 were excluded 
after reviewing the title and abstract. Finally, five stud-
ies were excluded after reviewing the complete article 
(Kawai et al. 1998; Skytting 2000; Nilsson et al. 1999; Hill 
et al. 2003; Canter et al. 2008). A total of 10 articles com-
prising 902 patients with synovial sarcoma fulfilled all of 
the inclusion criteria (Ladanyi et  al. 2002; Guillou et  al. 
2004; Panagopoulos et  al. 2001; Mezzelani et  al. 2001; 
Takenaka et  al. 2008; ten Heuvel et  al. 2009; Sun et  al. 
2009; Krieg et  al. 2011; Charbonneau et  al. 2013; Ren 
et al. 2013). The detailed selection procedure in the meta-
analysis is shown in Fig. 1 and Additional file 1.
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Study description and quality
Table  1 shows the principal characteristics of the 10 
studies included in the meta-analysis. The overall qual-
ity of the included studies evaluated by the NOS assess-
ment was adequate (mean 6.8 out of 9 stars) and there 
was no study with less than five stars. Low rating items 
were blindness of assessment and/or adequate follow-up 
period in the outcome categories (Table 2).
Meta‑analysis
DSS was analyzed together with OS to examine death-
related survival. There was a significant heterogene-
ity among the included eight studies consisting of 798 
patients (P = 0.0004, I2 = 74%); thus, the random effect 
model was used. Overall, the pooled HR for OS or DSS 
was 1.28 (95% CI 0.81–2.00), suggesting that no signifi-
cant difference existed between patients with SS18–SSX1 
and SS18–SSX2 (P = 0.29) (Fig. 2a).
The analysis of PFS and MFS was combined to exam-
ine disease-free survival. For seven studies composed of 
569 patients, a pooled HR and its 95% CI were calculated 
with the fixed effect model because of the mild heteroge-
neity among the studies (P = 0.06, I2 = 51%). The result 
showed that SS18–SSX1 may predict poorer PFS or MFS 
than SS18–SSX2, and that the pooled HR was 1.26 (95% 
CI 0.96–1.65), although the effect did not reach the level 
of statistical significance (P = 0.09) (Fig. 2b).
Publication bias
The funnel plots of OS or DSS (Fig. 3a) and PFS or MFS 
(Fig. 3b) were almost symmetric, suggesting a low risk of 
publication bias.
Discussion
Many studies have reported the prognostic impact of 
SS18–SSX fusion type on synovial sarcomas, but it still 
remains a matter of debate (Kawai et  al. 1998; Ladanyi 
et  al. 2002; Guillou et  al. 2004; Skytting 2000; Nilsson 
et  al. 1999; Hill et  al. 2003; Canter et  al. 2008; Panago-
poulos et al. 2001; Mezzelani et al. 2001; Takenaka et al. 
2008; ten Heuvel et al. 2009; Sun et al. 2009; Krieg et al. 
2011; Charbonneau et al. 2013; Ren et al. 2013). One of 
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partially duplicated patients (n = 3);
sample size smaller than 40 (n = 2)
Studies included in 
qualitative synthesis
(n =  10)




Records excluded, because of
duplication (n = 52)
Fig. 1 A flowchart of the article-selection process.
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the major problems with such studies is that many have 
limited sample power, analyzing only relatively small 
numbers of patients with synovial sarcoma. Therefore, 
we conducted meta-analysis to derive more robust esti-
mates of predictive performance of SS18–SSX fusion 
gene, which to our knowledge had not been studied pre-
viously. The results of our meta-analysis using the data of 
a sufficient number of patients indicate that there was no 
significant difference in OS or DSS between patients with 
SS18–SSX1 and SS18–SSX2, but that there were indica-
tions of SS18–SSX1 being an unfavorable prognostic fac-
tor of PFS or MFS.
Our study was based on thorough literature searches 
and careful data extraction, and included a large number 
Table 1 Clinical characteristics of the patients included in the meta-analysis
N/D not document, N number of patients, PCR reverse transcription-polymerase chain reaction, FISH fluorescent in situ hybridization, OS overall survival, DSS disease-
specific survival, PFS progression-free survival, MFS metastasis-free survival.
References Country Study design Total N Median/mean follow‑up
Panagopoulos et al. (2001) Sweden N/D 60 35 months
Mezzelani et al. (2001) Italy Consecutive 72 N/D
Ladanyi et al. (2002) USA Retrospective 242 2·7 years
Guillou et al. (2004) Switzerland Retrospective 165 37 months
Takenaka et al. (2008) Japan Retrospective 108 54 months
ten Heuvel et al. (2009) Netherlands N/D 45 55 months
Sun et al. (2009) China N/D 141 54 months
Krieg et al. (2011) Switzerland Retrospective 62 11.4 years
Charbonneau et al. (2013) USA Retrospective 103 N/D
Ren et al. (2013) China Retrospective 88 42·7 months
References Analyzed N Fusion gene analysis SS18–SSX1/SS18–SSX2 Survival analysis
Panagopoulos et al. (2001) 47 PCR 31/16 DSS, MFS
Mezzelani et al. (2001) 64 PCR 40/24 MFS
Ladanyi et al. (2002) 202 PCR or FISH 122/80 OS
Guillou et al. (2004) 141 PCR 99/42 DSS, MFS
Takenaka et al. (2008) 91 PCR 57/34 OS, MFS
ten Heuvel et al. (2009) 45 PCR or FISH 27/18 DSS, MFS
Sun et al. (2009) 141 PCR 50/91 DSS, MFS
Krieg et al. (2011) 43 PCR 30/13 OS
Charbonneau et al. (2013) 40 PCR 24/16 PFS
Ren et al. (2013) 88 PCR 47/41 OS
Table 2 Newcastle–ottawa quality assessment scale for cohort studies
References Selection Comparability Outcome Total score
Assessment 
of outcome




Panagopoulos et al. (2001) 4 2 0 0 0 6
Mezzelani et al. (2001) 4 2 0 0 1 7
Ladanyi et al. (2002) 4 2 1 0 1 8
Guillou et al. (2004) 4 2 1 0 1 8
Takenaka et al. (2008) 4 2 1 0 0 7
ten Heuvel et al. (2009) 4 2 0 0 0 6
Sun et al. (2009) 4 2 0 0 0 6
Krieg et al. (2011) 4 2 0 1 1 8
Charbonneau et al. (2013) 4 2 0 0 0 6
Ren et al. (2013) 4 2 0 0 0 6
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of patients after the methodological quality of study 
design assessments. The exclusion of studies with sample 
size smaller than 40 might contribute to the low risk of 
publication bias. However, our study still has several limi-
tations. Firstly, follow-up periods are not long enough to 
evaluate survival outcomes of synovial sarcoma (Table 1). 
This is particularly important because metastases and 
local recurrence are known to develop very late in syno-
vial sarcoma (Krieg et al. 2011). Secondly, bias could not 
be completely ruled out, despite our efforts to judge as 
fairly as possible. To minimize bias in the study selec-
tion and in the data extraction, reviewers performed 
this study blindly and independently. To ensure that all 
the selected articles were high-quality, only articles with 
six or more out of nine stars in the NOS assessment tool 
were selected. Thirdly, there was high and medium heter-
ogeneity of HR across the studies of survival analyses. I2 
represents the percentage of total variability in estimates 
caused by genuine between-study heterogeneity rather 
than by random sampling error, and was classified as fol-
lows: no heterogeneity (less than 25%), low heterogeneity 
(between 25 and 50%), medium heterogeneity (between 
51 and 75%), and high heterogeneity (greater than 75%) 
(Higgins and Thompson 2002). In the current study, 
the observed heterogeneity might be attributable to the 
patient group comprising a very heterogeneous popula-
tion where there was no agreement on surgical and adju-
vant treatment modalities.
Thus far, there have been two large studies including 
more than 100 patients with primary localized synovial 
sarcoma reporting the prognostic impact of SS18–SSX 
fusion type (Ladanyi et  al. 2002; Guillou et  al. 2004). 
However, these results do not seem to be conclusive, 
since the follow-up periods of both studies are too short 
to evaluate the survival of slow growth malignancy. The 
only prognostic study evaluating a follow-up of survivors 
a
b
Fig. 2 Forest plot of hazard ratios between SS18 and SSX fusion type for OS or DFS (a) and PFS or MFS (b). Square size of individual studies repre-
sents weight of study. Vertical lines represent 95% CI of pooled estimate. “Experimental” indicates patients with SS18–SSX1 fusion gene. “Control” 
indicates patients with SS18–SSX2 fusion gene.
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for a minimum of 10 years described that distant metas-
tases occurred at a mean of 5–7 years and advocated that 
patients with synovial sarcoma should be tracked for 
more than 10 years (Krieg et al. 2011). Prospective ran-
domized clinical trials with long follow-up cohorts using 
the same therapeutic strategy are ideal means of com-
pletely excluding all potential biases.
Conclusions
In conclusion, the meta-analysis of this study has sug-
gested that there was no significant difference in OS or 
DSS between patients with SS18–SSX1 and SS18–SSX2, 
but there were indications of SS18–SSX1 being an unfa-
vorable prognostic factor of PFS or MFS. In order to 
consolidate our results, meta-analysis including cohorts 
with a follow-up period spanning at least 10 years will be 
necessary.
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